Related Experiment Videos
Cardiac diastolic function in pediatric patients receiving doxorubicin
1Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Acta Oncologica (Stockholm, Sweden)
|January 1, 1994
Summary
Pediatric cancer patients receiving doxorubicin showed a slight decline in systolic function but no significant changes in diastolic function. Fractional shortening is preferred for monitoring cardiac health in these patients.
Area of Science:
- Cardiology
- Pediatric Oncology
- Cardiotoxicity
Background:
- Doxorubicin is a common chemotherapy agent used in pediatric cancers.
- Anthracyclines like doxorubicin can cause cardiotoxicity.
- Monitoring cardiac function in pediatric patients undergoing chemotherapy is crucial.
Purpose of the Study:
- To compare systolic and diastolic left ventricular function in pediatric patients treated with doxorubicin.
- To evaluate the impact of doxorubicin on cardiac function in children.
- To determine the most reliable parameters for assessing cardiac status during doxorubicin therapy.
Main Methods:
- Left ventricular function was assessed in 61 children before and after doxorubicin chemotherapy.
- Systolic function was measured using fractional shortening.
- Diastolic function was evaluated using A wave velocity, E wave velocity, E to A ratio, and deceleration time.
Main Results:
- A small but significant decline in systolic function (fractional shortening) was observed.
- No significant changes were detected in any measured parameters of diastolic function.
- Patients received low cumulative doses of doxorubicin, with most receiving it via continuous infusion.
Conclusions:
- Systolic function, estimated by fractional shortening, showed a decline in pediatric patients treated with doxorubicin.
- Current diastolic function parameters did not reveal significant changes.
- Fractional shortening is currently preferred over studied diastolic parameters for evaluating cardiac status in pediatric patients receiving doxorubicin.